Page 119 - OR-1-2

persistent androgen receptor signaling. Med Oncol. 72. Pauli C, Hopkins BD, Prandi D, et al. Personalized in vitro
2021;38:135. and in vivo cancer models to guide precision medicine.
Cancer Discov. 2017;7:462-477.
doi: 10.1007/s12032-021-01582-y
doi: 10.1158/2159-8290.cd-16-1154
61. Compérat E, Amin MB, Cathomas R, et al. Current best
practice for bladder cancer: A narrative review of diagnostics 73. Andrews MG, Kriegstein AR. Challenges of organoid
and treatments. Lancet. 2022;400:1712-1721. research. Annu Rev Neurosci. 2022;45:23-39.
doi: 10.1016/s0140-6736(22)01188-6 doi: 10.1146/annurev-neuro-111020-090812
62. Dyrskjøt L, Hansel DE, Efstathiou JA, et al. Bladder cancer. 74. Schafer ST, Mansour AAF, Schlachetzki JCM, et al. An in vivo
Nat Rev Dis Primers. 2023;9:58. neuroimmune organoid model to study human microglia
phenotypes. Cell. 2023;186:2111-2126.e20.
doi: 10.1038/s41572-023-00468-9
doi: 10.1016/j.cell.2023.04.022
63. Guo Z, Li Z, Wang J, et al. Modeling bladder cancer in the
laboratory: Insights from patient-derived organoids. Biochim 75. Tan R, Zhang Z, Ding P, et al. A growth factor-reduced
Biophys Acta Rev Cancer. 2024;1879:189199. culture system for colorectal cancer organoids. Cancer Lett.
2024;588:216737.
doi: 10.1016/J.BBCAN.2024.189199
doi: 10.1016/J.CANLET.2024.216737
64. Mullenders J, De Jongh E, Brousali A, et al. Mouse and
human urothelial cancer organoids: A tool for bladder cancer 76. Costa D, Venè R, Coco S, et al. SB202190 predicts BRAF-
research. Proc Natl Acad Sci U S A. 2019;116:4567-4574. activating mutations in primary colorectal cancer organoids
via Erk1-2 modulation. Cells. 2023;12:664.
doi: 10.1073/pnas.1803595116
doi: 10.3390/cells12040664
65. Kong JH, Lee H, Kim D, et al. Network-based machine
learning in colorectal and bladder organoid models 77. Salas-Silva S, Kim Y, Kim TH, et al. Human chemically-
predicts anti-cancer drug efficacy in patients. Nat Commun. derived hepatic progenitors (hCdHs) as a source of liver
2020;11:5485. organoid generation: Application in regenerative medicine,
disease modeling, and toxicology testing. Biomaterials.
doi: 10.1038/S41467-020-19313-8 2023;303:122360.
66. Lee SH, Hu W, Matulay JT, et al. Tumor evolution and drug doi: 10.1016/j.biomaterials.2023.122360
response in patient-derived organoid models of bladder
cancer. Cell. 2018;173:515. 78. Yin X, Mead BE, Safaee H, Langer R, Karp JM, Levy O.
Engineering stem cell organoids. Cell Stem Cell. 2016;18:
doi: 10.1016/j.cell.2018.03.017 25-38.
67. Wang L, Wang X, Zhu X, et al. Drug resistance in ovarian doi: 10.1016/j.stem.2015.12.005
cancer: From mechanism to clinical trial. Mol Cancer.
2024;23:66. 79. Workman MJ, Mahe MM, Trisno S, et al. Engineered human
pluripotent-stem-cell-derived intestinal tissues with a
doi: 10.1186/s12943-024-01967-3 functional enteric nervous system. Nat Med. 2017;23:49-59.
68. Kopper O, De Witte CJ, Lõhmussaar K, et al. An organoid doi: 10.1038/nm.4233
platform for ovarian cancer captures intra- and interpatient
heterogeneity. Nat Med. 2019;25:838-849. 80. Gjorevski N, Sachs N, Manfrin A, et al. Designer matrices
for intestinal stem cell and organoid culture. Nature.
doi: 10.1038/s41591-019-0422-6 2016;539:560-564.
69. Maenhoudt N, Defraye C, Boretto M, et al. Developing doi: 10.1038/nature20168
organoids from ovarian cancer as experimental and
preclinical models. Stem Cell Reports. 2020;14:717-729. 81. Janda CY, Dang LT, You C, et al. Surrogate Wnt agonists that
phenocopy canonical Wnt and β-catenin signalling. Nature.
doi: 10.1016/j.stemcr.2020.03.004 2017;545:234-237.
70. Polak R, Zhang ET, Kuo CJ. Cancer organoids 2.0: Modelling doi: 10.1038/nature22306
the complexity of the tumour immune microenvironment.
Nat Rev Cancer. 2024;24(8):523-539. 82. Magré L, Verstegen MMA, Buschow S, Van Der Laan LJW,
Peppelenbosch M, Desai J. Emerging organoid-
doi: 10.1038/s41568-024-00706-6 immune co-culture models for cancer research: From
71. Huang L, Holtzinger A, Jagan I, et al. Muthuswamy, ductal oncoimmunology to personalized immunotherapies.
pancreatic cancer modeling and drug screening using human J Immunother Cancer. 2023;11:e006290.
pluripotent stem cell- and patient-derived tumor organoids. doi: 10.1136/jitc-2022-006290
Nat Med. 2015;21:1364-1371.
83. Li Z, Ma L, Gao Z, et al. Identification and validation of
doi: 10.1038/nm.3973 tumor-specific T cell receptors from tumor infiltrating

Volume 1 Issue 2 (2025) 13 doi: 10.36922/OR025050008